

# EXTERNAL OUALITY ASSESSMENT 2023 MICROBIOLOGY

WWW.LABQUALITY.COM | INFO@LABQUALITY.FI

# Service information

#### Labquality – EQAS

Labquality is an independent Finnish external quality assessment provider. Labquality has more than 50 years of experience in helping clinical laboratories and POCT sites develop and maintain their performance. Labquality's EQA schemes are internationally recognized high quality programs. The EQA programs have a clinical scope with an educational touch. Part of the EQA production is outsourced to expert laboratories and national partners.

#### Integrated EQA service (EQA<sup>3</sup>)

Labquality is the first EQA provider that has integrated pre-analytical, analytical and post-analytical phases to its EQA programs. Advanced and traditional EQA schemes have been designed to fully support the total quality management system of the participating laboratories and fulfill ISO 15189 requirements concerning the extra-analytical phases. In addition to the samples, the integrated schemes include pre- and/or post-analytical questionnaires concerning the scope of the scheme.

#### **Quality management**

Labquality's management system is certified according to ISO 9001 (DQS) and the main EQA schemes are accredited according to ISO 17043 (PT02/FINAS). The scope of accreditation is available on the FINAS website: **www.finas.fi**, and the accreditation status of the EQA schemes is available on our website: **www.labquality.fi/en**. The list of accredited schemes will be provided upon request.

#### **EQA service availability**

Labquality has customers in over 50 countries in Europe, Asia, America and North Africa. Service is localized by 40 national partners. All digital schemes, including pre-analytical schemes and diagnostic schemes for anatomic pathology, are available globally. With only a few exceptions all schemes are globally available through national partner. For direct customers, the program selection is limited to the schemes with stabile and non-hazardous sample materials.

#### **Enrolment and prices**

Labquality has annual programs and pricing. Participants shall place their orders for the following year before the end of November to ensure their participation in all needed EQA rounds. Enrolment is possible during the calendar year, but only part of the EQA rounds may be available. To place an order, please contact our national partner in your country or Labquality's customer service at info@labquality.com

#### Distributions

Labquality's specimen logistics system is accepted and continuously audited as part of accreditation according to the ISO 17043 (PT02/FINAS) standard. Specimens are shipped according to the annual schedule. Labquality retains the right to make changes in the schedule.

#### LabScala EQA portal

Partners and participants are able to handle the whole EQA process from orders to reports through a modern web based software, LabScala. The EQA process is designed to go along with the laboratory process from pre-analytics to post-analytics. Easy availability and user-friendly interface guarantee an advanced experience.

#### Certificate

A certificate of participation will be provided upon request at the end of the calendar year. The certificate refers to EQA reports to evaluate the performance of the participant.

#### **Customer service**

Please contact Labquality's international partners (listed on our website: www.labquality.com) or our customer service: info@labquality.fi

# How to use the catalogue



**Results processed:** The number shows how many results from different analyzers or tests within the same laboratory are allowed depending on scheme, when the sample volume is sufficient. Schemes marked with \* allow multiple results reporting only, if they are analyzed with different methods.

# Microbiology

The microbiological EQA programs are suitable for clinical laboratories and POCT sites performing testing in the areas of bacterial serology, bacteriology, mycology, parasitology and virology. While the selection includes schemes for antigen detection, antibody detection, culture, microscopy, and PCR tests, solutions for versatile needs are available. Authentic single donor samples are included in multiple schemes.

#### Microbiology » Bacterial Serology

		1	2	3	4	5	6	7	8	9	10	11	12	
5840 Antistreptolysin			•			•			•			•		
<b>Specimens:</b> 2 liquid human serum or plasma samples, 0.4 mL Authentic, commutable, single donor samples.		Exami	nation	ı <b>s:</b> Qua	litative	e and q	uantita	itive AS	50					
		1	2	3	4	5	6	7	8	9	10	11	12	1
5950 Bordetella pertussis, antibodies		•			•				•			•		
Specimens: 2 liquid human serum samples, 0.3 mL		Exami IgG & I	<b>nation</b> gM, po	i <b>s:</b> <i>B. p</i> i ost-ana	<i>ertussi:</i> alytical	s IgA, Ig clinica	gG & Ig I interp	M antil retatio	oodies, n	Pertus	ssis tox	kin IgA,		EQA³
		1	2	3	4	5	6	7	8	9	10	11	12	
5960 Borrelia burgdorferi, antibodies, European origin		•			•				•			•		
<b>Specimens:</b> 2 liquid human serum or plasma samples, 0.5 mL Authentic, commutable, single donor samples.		<b>Exami</b> clinica	<b>nation</b> I interp	<b>is:</b> B. bi pretatio	urgdor; on	feri IgG	, IgM a	nd tota	ıl antib	odies,	post-a	nalytic	al	EQA³
		1	2	3	4	5	6	7	8	9	10	11	12	
5965 CXCL 13 Chemokine		•					•							z
Specimens: 2 liquid samples		Exami	nation	s: Chei	mokine	CXCL1	13 deteo	ction						EV
		1	2	3	4	5	6	7	8	9	10	11	12	
5620 <i>Chlamydia pneumoniae</i> , antibodies	3			•			•		<u> </u>	•	<u> </u>		•	
Specimens: 3 liquid serum or plasma samples, 0.4 mL		Exami clinica	<b>nation</b> I interp	o <b>s:</b> C. pi pretatio	neumo on	niae Ig	A, IgG,	lgM an	tibodie	≥s, post	t-analy	rtical		QA
		1	2	3	4	5	6	7	8	9	10	11	12	_
5851 Francisella tularensis, antibodies					•						•			
Specimens: 3 liquid human serum or plasma samples, 0.5 mL		Exami	nation	ı <b>s:</b> Frar	ncisella	tulare	nsis IgC	i, IgM a	ind tot	al antil	bodies			
		1	2	3	4	5	6	7	8	9	10	11	12	
5860 Helicobacter pylori, antibodies	3			•			•			•			•	ő
Specimens: 2 liquid human serum or plasma samples, 0.4 mL		qualita	ative te	ests, po	ost-ana	alytical	clinica	l interp	retatio	n				~
Examinations: H. pylori IgA, IgG and total antibodies, quantitative and		Notes	For cl	inical la	aborato	ories ar	nd POC	T sites						0 CT
		1	2	3	4	5	6	7	8	9	10	11	12	
5980 Mycoplasma pneumoniae, antibodies			•			•				•		•		四
Specimens: 2 liquid human serum or plasma samples, 0.3 mL	9	Exami	nation	<b>s:</b> М. р	neumo	oniae Is	gG, IgM	and to	tal ant	ibodie	s, post	-analyt	ical	١Å٩
Authentic, commutable, single donor samples.		clinica	l interp	, pretatio	on	-						·		В
		Notes	For cl	inical la	aborato	ories ar	nd POC	T sites						Ē
		1	2	3	4	5	6	7	8	9	10	11	12	
5880 Syphilis serology	3*		•				•				•		•	
<b>Specimens:</b> 2 liquid human serum samples, 0.6 mL Authentic commutable single donor samples		Exami	nation	i <b>s:</b> Carc	liolipin on	, Trepo	nema p	oallidur	n antib	odies,	post-a	inalytic	al	ĘQA₃

### Microbiology » Bacteriology

	1	2	3	4	5	6	7	8	9	10	11	12
5050 Bacteriological staining, direct (digital images)				•						•		
Specimens: 3 cases, 3–9 digital images	Exami bacter	<b>nation</b> iologica	<b>s:</b> Inter al Gram	pretati 1 staini	on of c ng of c	ligital i linical :	mages sample	taken s	from d	lirect		
	1						7			10	11	17
5100 Blood culture		2	•	4	•	D	/	0	5	•		•
Specimens: 2 lyophilized samples. Brief case histories are also given. Fresh blood is needed for specimen preparation. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains.	Exami Notes	nation: Fresh	s: Cultı blood i	ure, ide is need	ntifica ed but	tion, ai not ind	ntimicr cluded i	obial s in the s	uscept shipme	ibility ent		
	1	2	3	4	5	6	7	8	9	10	11	12
5101 Blood culture, screening			•		•					•		•
<b>Specimens:</b> 2 lyophilized samples. Brief case histories are also given. Fresh blood is needed for sample preparation.	Exami The sc growth	nation: heme i 1. Note	<b>s:</b> Cultu s also s <b>s:</b> Fres	ure, pre suitable h blooc	limina e for st l is nee	ry iden em cel ded bu	tificati I banks It not ii	on usir screer nclude	ng Gran ning on d in the	n stair ly for j e shipr	iing. possible ment	e
	1	2	3	4	5	6	7	8	9	10	11	12
5150 Cerebrospinal fluid, bacterial culture		•			•				•			•
Specimens: 2 lyophilized samples. Brief case histories are also given. Examinations: Culture and identification. The scheme is also suitable for laboratories performing screening and reporting merely a preliminary identification.	Notes detect	See al ion	so sche	eme 53	03 Mei	ningitis	s-encep	ohalitis	i multij	plex, n	ucleic a	acid
	1	2	3	4	5	6	7	8	9	10	11	12
5612 Chlamydia trachomatis and Neisseria gonorrhoeae nucleic acid detection			•		•			•			•	
Specimens: 3 simulated swab/urine samples, 2 mL Examinations: Detection of <i>C. trachomatis</i> and <i>N. gonorrhoeae</i> nucleic acid	Notes nuclei	See al acid d	so sche etectio	eme 53 on	02 Sex	ually t	ransmi	tted di	seases	multi	plex,	
	1	2	3	4	5	6	7	8	9	10	11	12
5200 Clostridioides difficile, culture and toxin detection	)	•			•			•			•	
Specimens: 2 lyophilized mixtures of bacteria	<b>Exami</b> (GDH), <i>C. diff</i> i	nation: toxin c cile stra	<b>s:</b> This letectio ains als	schem on and so inclu	e inclu direct Ided.	des <i>C. (</i> nucleic	difficile : acid de	e cultur etectio	e, antig in. Hyp	gen de ervirul	ent	1
	1	2	3	4	5	6	7	8	9	10	11	12
5202 Clostridioides difficile, extra set of samples		•			•			•			•	
Specimens: 2 lyophilized mixtures of bacteria	Notes	Only ii	n conne	ection	with sc	heme	5200					
	1	2	3	4	5	6	7	8	9	10	11	12
5201 Clostridioides difficile, nucleic acid detection		•			•			•			•	
Specimens: 2 lyophilized mixtures of bacteria	Exami difficil Notes	<b>nation</b> e strair 5200 i	<b>s:</b> C. dij Is also Include	fficile d include es also t	irect n ed. this exa	ucleic a aminat	acid det tion	tection	. Нуре	rvirule	nt C.	
	1	7	R	А	5	F	7	Q	q	10	11	17
5191 Faecal bacterial pathogens multiplex, nucleic acid detection		2	5	•	5	•	/	0	5	•		•
Specimens: 3 samples. Either lyophilized mixtures of bacteria and/or simulated samples, 1 mL. Examinations: Direct nucleic acid detection. Pathogens included are Aeromonas, Campylobacter, <i>E. coli</i> EHEC (stx1/stx2), <i>E. coli</i> EAEC, <i>E. coli</i> EIEC,	<i>E. coli</i> <b>Notes</b> listed	EPEC, <i>E</i> During pathog	E <i>. coli</i> E g the pe ens wil	ETEC, P eriod of II be co	lesiom f one ca vered.	onas, S alenda	Salmon r year, a	iella, Sl a comp	higella rehens	and Yo sive se	ersinia. lection	of

	1	2		3	4	5	6	7	8	9	10	11	12	
5230 Mycobacterium tuberculosis, drug resistance				•			•			•			•	
Specimens: 2 simulated samples, 1 mL	Exami suscep	i <b>natic</b> otibili	o <b>ns:</b> A ty an	Aycol d iso	bacte niazi	rium ti d susc	ubercule eptibili	osis nuo ty	cleic ac	id dete	ction,	rifamp	icin	NEW
5190 Faecal culture	1	2		3	4	5	6	7	8	9	10	11	12	٦
	)					4.49.49.4				Dett		l.		
Specimens: 2 lyophilized mixtures of bacteria	are Ae	romo	nas, l	Camp	re ani pylob	a airec acter, l	Plesiom	c ació ó onos, S	almon	on. Patr ella, Sh	igella a	includ	ea sinia.	
5080 General Bacteriology 1 (aerobes and anaerobes)	1	2		3 •	4	5	6	7	8	9	10	11	12	
Specimens: 4 lyophilized mixtures of microbes: both pathogens and normal flora. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Brief case histories are also given. Pre- and/or post-analytical cases in part of the rounds.	Exami testin Notes	<b>inatio</b> g, pre : 508	ons: l: e- anc O incl	solat 1/or p ludes	tion o post- s 508	f path analyt 1, Gen	ogens a ical cas eral Bac	and ant es teriolo	imicrol	bial sus	sceptib	ility		ΕQA <sup>3</sup>
	1	2		3	4	5	6	7	8	9	10	11	12	
5081 General Bacteriology 2 (aerobes)	)			•		•				•			•	-
<b>Specimens:</b> 2 lyophilized mixtures of microbes: both pathogens and normal flora. The specimens intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Brief case histories are also given. Pre- and/or post-analytical cases in part of the rounds.	Exami testin Notes	inatio g, pre : 508	o <b>ns:</b> li e- and O Ger	solat 1/or p neral	ion o post- Bact	f path analyt eriolog	ogens a ical cas gy 1 incl	and ant es udes 50	cimicrol 081	bial sus	sceptib	ility		EQA³
	1	2		3	4	5	6	7	8	9	10	11	12	_
5041 Gram stain, blood culture	•				•			•			•			
<b>Specimens:</b> 2 air-dried, unfixed microbe suspensions on slides. Brief case histories also given.	Exami	inatio	ons: S	Stain	ing a	nd mic	roscop	/						
	1	2		3	4	5	6	7	8	9	10	11	12	
5040 Gram stain, colonies	•				•			•			•			
Specimens: 3 air-dried, unfixed microbe suspensions on a slide	Exami	inatio	ons: S	Stain	ing a	nd mic	roscop	/						
	1	2		3	4	5	6	7	8	9	10	11	12	
5596 Helicobacter pylori, antigen detection in faeces	)			•			•			•			•	8
Specimens: 3 samples: lyophilized faecal or swab Examinations: Antigen detection	Notes	: For	clinic	al lat	borat	ories a	nd POC	T sites	i					9
	1	2		3	4	5	6	7	8	9	10	11	12	_
3*	)			•		•				•			•	Po
Specimens: 3 simulated urine samples	Exami	inatio	ons: L	.egio	nella	antige	en dete	tion						Ч
	1	2		3	4	5	6	7	8	9	10	11	12	_
5220 Mycobacterial culture and stain				•			•			•			•	
Specimens: 2 lyophilized samples and 2 fixed smears on slides	detect	tion, a	acid-f	fast s	staini	ng and	d micros	сору						
Examinations: Detection of <i>Mycobacterium tuberculosis</i> , <i>Mycobacterium tuberculosis</i> complex and atypical mycobacteria: culture, direct nucleic acid	Notes	: See	also	prod	uct 5	250 IG	RA for	M. tube	erculos	is				
5221 Mycobactorial nucleic acid detection	1	2		3	4	5	6	7	8	9	10	11	12	
	)			•			-							-
Specimens: 2 lyophilized samples Examinations: Direct nucleic acid detection	Notes order	: 522 scher	0 incl ne 52	udes 22	s also	this e	xamina	tion. F	or addi	tional s	set of s	ample	5,	
	1	2		3	4	5	6	7	8	9	10	11	12	_
5222 Mycobacteria, extra set of samples				•			•			•			•	
Specimens: 2 lyophilized samples	Notes	: Only	y in co	onne	ction	with	cheme	5220 c	or 5221					

	5240 Mycobacterial stain	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 2 fixed smears on slides	Exami	nation	s: Acid	-fast s	taining	and m	icrosco	ру				
	5120 Neisseria gonorrhoeae (Gc), culture and susceptibility testing	1	2	3	4	5	6	7	8	9	10	11	12
	<b>Specimens:</b> 2 lyophilized mixtures of microbes. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains.	<b>Exami</b> Also si	nation uitable	s: Cult for lat	ure, ide oorator	entifica ies perf	tion an forming	d antir g prelin	nicrobi ninary s	al susc screeni	eptibil ng.	ity test	ting.
		1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 2 lyophilized mixtures of bacteria Examinations: Culture	Notes	: 5190 a	also inc	ludes	5180	•				•		•
		1	2	3	4	5	6	7	8	9	10	11	12
н	5599 Streptococcus agalactiae (GBS), nucleic acid detection				•		•			•		•	
POC	Specimens: 2 swab samples. Samples also include normal flora. Examinations: Direct nucleic acid detection	Notes	: See al	lso pro	duct 5!	594 for	S. agal	actiae	(GBS) c	ulture.			
		1	2	3	4	5	6	7	8	9	10	11	12
	5594 Streptococcus agalactiae (GBS), culture				•		•			•		•	
	Specimens: 2 lyophilized samples. Samples include pathogens and/or normal flora.	Exami Notes	<b>nation</b> : See al	<b>s:</b> Cult Iso pro	ure duct 5!	599 for	direct r	nucleic	acid de	tectio	n.		
		1	2	3	4	5	6	7	8	9	10	11	12
t	5598 Streptococcus pneumoniae, antigen detection in urine			•		•				•			•
8	Specimens: 3 simulated urine specimens	Exami	nation	<b>s:</b> S. pi	пеито	<i>niae</i> an	tigen d	etectio	n				
		1	2	3	4	5	6	7	8	9	10	11	12
L,	5595 Streptococcus pyogenes (Group A), antigen detection in pharyngeal sample (3*)			•		•				•			•
PC	Specimens: 3 simulated pharyngeal samples Examinations: Antigen detection	Notes: kits.	For cli	inical la	aborato	ories an	Id POCT	۲ sites.	Three	results	if used	d differ	rent
		1	2	3	4	5	6	7	8	9	10	11	12
	5593       Streptococcus pyogenes (Group A), nucleic acid detection in pharyngeal sample         3*			•		•				•			•
	Specimens: 3 simulated pharyngeal samples Examinations: Nucleic acid detection	n. Notes	: Three	result	s if use	ed diffe	rent kit	s.					
		1	2	3	4	5	6	7	8	9	10	11	12
	5073 Surveillance for multidrug resistant bacteria, gramnegative rods		•				•			•		•	
	Specimens: 1 lyophilized mixture of microbes; including pathogens and/or normal flora	Exami of mul and P.	<b>nation</b> tidrug <i>aerugii</i>	<b>s:</b> The resista nosa) t	schem ant gra by culti	e is into mnegat ure and	ended f tive rod /or dire	for labo s (e.g. ct nucl	oratorie CPE, ES leic ació	s perfo SBL, M d detec	orming DR <i>Aci</i> tion m	screen netoba ethod	ing acter
		1	2	3	4	5	6	7	8	9	10	11	12
	5071 Surveillance for multidrug resistant bacteria, MRSA		•				•			•		٠	
	<b>Specimens:</b> 1 lyophilized mixture of microbes; including pathogens and/or normal flora	Exami of MR direct	<b>nation</b> SA (me nucleic	s: The ethicilli acid d	schem n resis etectic	e is into tant <i>St</i> on meth	ended f aphylo nod	for labo coccus	oratorie aureus	s perfo ) by cu	orming Iture a	screen nd/or	iing

	1	2	3	4	5	6	7	8	9	10	11	12
5072 Surveillance for multidrug resistant bacteria, VRE (1	$\mathbf{b}$	•				•			•		•	
Specimens: 1 lyophilized mixture of microbes; including pathogens and/or normal flora	Exami of VRI acid d	<b>ination</b> E (vanc etectio	<b>s:</b> The omycii n metl	schem n-resist hod	e is int tant en	ended Iteroco	for lab cci) by	oratorio culture	es perf and/o	orming r direct	screen nuclei	ling c
	1	2	3	4	5	6	7	8	9	10	11	12
5140 Throat streptococcal culture			•		•			•			•	
Specimens: 3 lyophilized mixtures of bacteria	Exami	ination	s: Cult	ure an	d ident	ificatio	on of gr	oup A,	C and (	G strep	tococci	
	1		2				7			10	11	17
5060 Urine culture, quantitative screening		2	•	4		•		<u> </u>	•			•
Specimens: 2 lyophilized samples and dilutor. Brief case histories also given. Pre- and/or post-analytical cases in part of the rounds.	Exami Notes analyz	ination: : Schen :ers.	<b>s:</b> Cultı ne 3170	ure and ) availa	quanti ble for	tation, urine b	pre-an acterial	d/or po screen	ing wit	lytical i h autor	ndicato nated	ırs Ş
	1	2	3	4	5	6	7	8	9	10	11	12
5065 Urine culture, quantitative screening, identification and susceptibility			•			•			•			•
<b>Specimens:</b> 2 lyophilized samples and dilutor. Brief case histories also given. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Pre- and/or post-analytical cases in part of the rounds.	Exami suscep Notes analyz	ination ptibility : Schen :ers.	<b>s:</b> Cult / testir ne 317C	ure, qu 1g, pre- ) availa	antita and/or ble for i	tion, id r post-a urine ba	entifica analytic acterial	ation a cal indi screen	nd anti cators ing wit	imicrot h autor	vial nated	Ş
Microhiology » <b>Mycology</b>												
F261 Europhisterions public sold detection	1	2	3	4	5	6	7	8	9	10		12
Section Simulated samples. The samples may include yeasts.	Notes	: Test s	electio	on of th	e parti	cipatin	le lab is	taken	into co	onsider	 ation ir	1
dermatophytes and moulds. <b>Examinations:</b> Nucleic acid detection according to laboratory's own test selection.	result	proces	sing.				5					2
	1	2	3	4	5	6	7	8	9	10	11	12
5260 Fungal culture			•		•				•		•	
<b>Specimens:</b> 3 lyophilized samples. Brief case histories also given. The samples include moulds, dermatophytes and yeasts.	<b>Exam</b> i of yea	<b>ination</b> st strai	<b>s:</b> Cult ns.	ure an	d ident	ificatio	on. Anti	imicrob	ial sus	ceptibi	lity tes	ting
Microbiology » <b>Parasitology</b>												
5472 Exercite Smultiplex nucleic acid detection	1	2	3	4	5	6	7	8	9	10	11	12
								-				
Specimens: 3 lyophilized samples	Exam fragili	s, Enta	<b>s:</b> Nuc moebc	leic aci histol	d deter <i>ytica</i> ar	nd <i>Giar</i>	t Crypto dia lan	osporid 1blia.	ium, D	ientam	oeba	
	1	7	3	4	5	6	7	8	9	10		12
5430 Malaria, antigen and nucleic acid detection	*)	•			•			•			•	
Specimens: 3 whole blood samples	Notes	: For cli	inical l	aborati	ories au	nd POC	T sites					7
<b>Examinations:</b> Antigen and nucleic acid detection. Target antigens: HRP2 and/or pLDH and/or aldolase.	notes						, sites					-
	1	2	3	4	5	6	7	8	9	10	11	12
5462 Malaria screening, Giemsa stain	)	•			•			•			•	
Specimens: 2 methanol fixed or Giemsa stained smears. Brief case histories also given.	Exami	ination	s: Preli	minary	screen	ing of n	nalaria	plasmo	dia			
	1	2	3	4	5	6	7	8	9	10	11	12
5463 Malaria screening, MGG stain		•			•			•			•	
Specimens: 2 methanol fixed or May-Grünwald-Giemsa stained smears. Brief	Exami	ination	s: Preli	minary	screen	ing of n	nalaria	plasmo	dia			
case materies are also given												

		1	2	3	4	5	6	7	8	9	10	11	12
	5460 Parasites in blood, Giemsa stain		•			•			•			•	
	<b>Specimens:</b> 2 methanol fixed or Giemsa stained smears. Brief case histories also given.	<b>Exami</b> blood	<b>nation</b> parasit	<b>s:</b> Scre es	ening a	ind ide	ntificat	tion of	malaria	a plasn	nodia a	nd oth	er
	5470 Parasites in blood Giemsa stain virtual microscopy	1	2	3	4	5	6	7	8	9	10	11	12
VIRTUAL	Specimens: 2 virtual whole slide images of Giemsa stained smears prepared by using a scanner microscope. Brief case histories also given.	Exami blood	<b>nation</b> parasit	<b>s:</b> Scre es	ening a	and ide	ntifica	tion of	malaria	a plasn	nodia a	ind oth	ier
		1	2	3	4	5	6	7	8	9	10	11	12
	5461 Parasites in blood, MGG stain	,	•		-	•		,	•			•	12
	Specimens: 2 methanol fixed or May-Grünwald-Giemsa stained smears. Brief case histories are also given.	Exami blood	<b>nation</b> parasit	<b>s:</b> Scre es	ening a	and ide	ntifica	tion of	malaria	a plasn	nodia a	ind oth	ier
		1	2	3	4	5	6	7	8	9	10	11	12
Ļ	5471 Parasites in blood, MGG stain, virtual microscopy											•	
VIRTUA	<b>Specimens:</b> 2 virtual whole slide images of MGG stained smears prepared by using a scanner microscope. Brief case histories also given.	<b>Exami</b> blood	<b>nation</b> parasit	<b>s:</b> Scre es	ening a	and ide	ntifica	tion of	malaria	a plasn	nodia a	ind oth	ier
		1	2	3	4	5	6	7	8	9	10	11	12
	5440 Parasites in faeces		•			•			•			•	
	Specimens: 3 stool samples in formalin. Brief case histories also given.	<b>Exami</b> parasi	<b>nation</b> tes)	s: Scre	ening a	and ide	ntifica	tion of i	intestii	nal par	asites	(ova ar	nd
		1	2	3	4	5	6	7	8	9	10	11	12
AL	5450 Parasites in faeces, virtual microscopy				•						•		
VIRTU	<b>Specimens:</b> Virtual whole slide images of stool samples in formalin prepared by using a scanner microscope. Brief case histories also given.	<b>Exami</b> parasi	<b>nation</b> tes)	s: Scre	ening a	and ide	ntifica	tion of i	intestii	nal par	asites	(ova ar	nd
		1	2	3	4	5	6	7	8	9	10	11	12
	5420 Toxoplasma, antibodies		•			•			•			•	
EQA₃	<b>Specimens:</b> 3 liquid human plasma samples, 0.7 mL each. Brief case histories also given. Authentic commutable samples: Each sample batch originates from a single human donor.	<b>Exami</b> post-a	nation inalytic	s: Toxo al clini	plasm cal inte	a IgA, I erpreta	gG, IgN tion	1 and to	otal an	tibodie	es, IgG a	avidity	,
		1	2	З	4	5	6	7	8	9	10	11	12
н	5473 Trichomonas vaginalis, detection		•		•				•		•		
ğ	Specimens: 3 simulated samples	Exami	nations	: Deteo	tion of	Trichor	monas	vaginal	is antig	en and	nucleio	: acid (I	VAT)
	Microbiology » <b>Virology</b>	1	2	з	4	5	6	7	8	9	10	11	12
	5556 HSV1&2/VZV/ <i>T. pallidum</i> , nucleic acid detection				•			•					
NEW	Specimens: 2-3 samples simulating swab samples taken from lesions	Exami	nation	s: Nucl	eic acid	detect	tion of	HSV1, H	ISV2, V	/ZV, Tre	eponen	na palli	idum
		1	2	3	4	5	6	7	8	9	10	11	12
	5651 CMV and EBV, nucleic acid detection, quantitative			•						•			
	Specimens: 5 samples simulating plasma, 1.5 mL Examinations: CMV and EBV NAT (quantitative).	Notes	: Quant	itative	result	proces	sing						
		1	2	3	4	5	6	7	8	9	10	11	12
	5650 Cytomegalovirus, antibodies		•			•				•			•
€QA³	<b>Specimens:</b> 3 liquid human plasma samples, 0.7 mL. Authentic commutable samples: each batch originates from a single human donor.	<b>Exami</b> post-a	nation malytic	s: Cyto al clini	megalo cal inte	ovirus I erpreta	gG, IgN tion	1 and to	otal an	tibodie	es, IgG a	avidity	and

	1	2		3	4	5	6	7	8	9	10	11	12	
5635 Dengue virus, antibodies and antigen detection				•			•			•		•		В
Specimens: 3 human serum or plasma samples, 0.5 mL. Authentic,	Exam	inatio	ons:	Deng	gue vir	us IgC	and Ig	M antil	oodies,	Dengu	e virus	antige	n	9
commutable samples from a single human donor or occasionally simulated	(NS1)	and p	ost-	anal	ytical	clinica	l interp	oretatio	n					ő
samples.														~
	1	2		3	4	5	6	7	8	9	10	11	12	
5640 EBV mononucleosis, POCT 3	)	•				•				•			•	
Specimens: 3 liquid human plasma samples, 0.5 mL. Authentic commutable	Exam	inatio	ons:	Mon	Ab									ŎĊŢ
samples: each batch originates from a single human donor.	Notes	: For	clini	cal la	borat	ories a	ind PO	CT sites	i					
	1	2		3	4	5	6	7	8	9	10	11	12	
5641 EBV mononucleosis, specific antibodies		•				•				•			•	
Specimens: 3 liquid human plasma samples, 1.4 mL. Authentic commutable samples: each batch originates from a single human donor.	Exami post-a	inatio analyt	ons: tical	EBN/ clinio	A AbG cal int	, EBV erpret	VCA Al ation	oG, EBV	VCA A	.bM, Igi	G Avidit	ty and		EQA <sup>3</sup>
	1	2		3	4	5	6	7	8	9	10	11	12	
3032 Repatitis A, antiboules														四
<b>Specimens:</b> 3 liquid human plasma samples, 0.6 mL. Authentic commutable samples: each batch originates from a single human donor.	Exam interp	<b>inatio</b> pretat	ons: ion	HAV	Δb, Н <i>і</i>	AVA bN	1, HAV	AbG ani	d post-	analyti	cal clini	ical		Ą
	1	2		3	4	5	6	7	8	9	10	11	12	
FORA-FORE Hepatitis B and C, serology, specimen volume														
0.6 mL / 1.2 mL / 2.0 mL	)													
Specimens: 3 liquid human plasma samples, 0.6 / 1.2 or 2.0 mL.	Volun	ne sp	ecifi	c pro	duct o	odes:								四
Authentic commutable samples: each batch originates from a single human donor.	5094: 5095:	for 0 for 1.	.6 m 2 ml	L hui _ hun	man p nan pl	lasma lasma	specin specin	nens 1ens						Ā
Examinations: HBcAb, HBcAbM, HBeAb, HBeAg, HBsAb (qual), HBsAg,	5096:	for 2.	.0 m	L hui	nan p	lasma	specir	nens						
HCVAb, HCVAbCt and post-analytical clinical interpretation														
	1	2		3	4	5	6	7	8	9	10	11	12	_
5093 Hepatitis B, s-antigen antibodies, quantitative	•				•			•			•			_
Specimens: 2 liquid human plasma or serum samples, 0.5 mL. Authentic	Exam	inatio	ons:	HBs/	Ab (an	ti-HB	s), quai	ntitativ	е					
commutable samples: each batch originates from a single human donor.														
	1	2		3	4	5	6	7	8	9	10	11	12	7
5679 Hepatitis B virus, nucleic acid detection (DNA)	)			•		•				•		•		
Specimens: 3 lyophilized or liquid plasma samples, 1.2 mL	Exam	inatio	ons:	HBV	DNA,	quant	itative	and/or	qualita	ative ni	ucleic a	cid		
	ueteci	LIUII												
	1	2		3	4	5	6	7	8	9	10	11	12	-
5678 Hepatitis C virus, nucleic acid detection (RNA)	)			•		•				•		•		
Specimens: 3 lyophilized or liquid plasma samples, 1.2 mL	<b>Exam</b> detect	<b>inatic</b> tion	ons:	HCV	RNA,	quant	itative	and/or	qualita	ative ni	ucleic a	cid		
	1	2		3	А	5	6	7	8	q	10	11	17	
5682 Hepatitis E, antibodies				5		•						•	12	
Specimens: 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.	<b>Exam</b> clinica	inatio	ons: erpre	Hepa tatio	atitis I n.	E virus	lgG an	d IgM a	ntibod	ies, po	st-anal	ytical		EQA <sup>™</sup>
5555 Hernes simplex 1 and 2 antibodies	1	2		3	4	5	6	7	8	9	10	11	12	7
3									•   •					
Specimens: 3 liquid human plasma or serum samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor. Occasionally simulated samples.	Exam 2 IgG	inatio	ons:	HSV	igG (q	ualita	tive/qı	lantita	live), H	SV IgM	, HSV-1	igG, H	SV-	

		1	2	3	4	5	6	7	8	9	10	11	12
	5680 HIV-1, nucleic acid detection (RNA)			•		•				•		•	
	Specimens: 3 lyophilized or liquid plasma samples, 1.2 mL	Exam detec	<b>inatio</b> tion	ns: HIV	/-1 RNA	, quant	itative	and/or	qualita	ative nu	icleic a	cid	
		1	2	3	4	5	6	7	8	9	10	11	12
	5091 HIV, antibodies and antigen detection	)	•			•		,	•			•	
EQA <sup>3</sup>	Specimens: 3 liquid human plasma 0.7 mL	Exam confi may i	<b>inatio</b> r mator nclude	ns: HIV y tests HIV-1 (	/AgAb ( , post-a or HIV-2	combo) analytic 2.	, HIVAŁ al clinic	o, HIVA al inte	g, HIVA rpretat	\bCt: pr ion. Po	imary sitive s	and specim	iens
		1	2	3	4	5	6	7	8	9	10	11	12
	5090 HIV, antibodies and antigen detection, POCT		•			•			•			•	
POCT	Specimens: 3 liquid human plasma 0.5 mL Examinations: HIVAb and HIVAgAb primary tests (POCT)	Note	: Sche	me 50!	91 is foi	<sup>,</sup> clinica	l labora	tories					
		1	2	3	4	5	6	7	8	9	10	11	12
	5086 Human papillomavirus, nucleic acid detection	•			•			•			•		
	Specimens: 2 simulated samples, 1 mL Examinations: High-risk human papillomavirus NAT, hrHPVNAT	Note	: Suita	ible for	r nuclei	c acid m	nethods	s used i	n cervi	cal can	cer scre	ening	
		1	2	3	4	5	6	7	8	9	10	11	12
	5089 Human T-cell lymphotropic virus, antibodies		•			•			•			•	
EQA	<b>Specimens:</b> 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.	Exam clinica	<b>inatio</b> al inter	<b>1s:</b> HTl pretati	LVAb: p ion. Pos	rimary a sitive sa	and cor amples	nfirmat may in	ory tes clude H	ts, pos ITLV-1 (	t-analy or HTL\	rtical /-2.	
		1	2	3	4	5	6	7	8	9	10	11	12
	5670 Influenza virus A+B and RS virus, nucleic acid detection		•									•	
	Specimens: 5 artificial samples. 1 mL Examinations: InfANAT, InfBNAT, RSVNAT	Note: detec	: See a tion	also sch	heme 5	300 Re	spirato	ry infec	tions r	nultiple	ex, nuc	leic aci	id
		1	2	3	4	5	6	7	8	9	10	11	12
	5671 Influenza virus A+B, antigen detection		•									•	
POCT	Specimens: 3 liquid and/or swab samples. Examinations: InfAAg, InfBAg	Note: for IF.	<b>s:</b> For cl A or NA	linical   AT met	laborat hods, p	ories ar lease s	nd POCT ee sche	F sites. me 567	The sa 70 or 55	mples 562.	are not	: suital	ble
		1	2	3	4	5	6	7	8	9	10	11	12
	5668 Measles virus, antibodies	•			•			•			•		
EQA	<b>Specimens:</b> 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.	Exam clinica	<b>inatio</b> al inter	<b>1s:</b> Mei pretati	asles vi ion	rus IgG	and IgN	M antib	odies a	and pos	t-anal	ytical	
		1	2	3	4	5	6	7	8	9	10	11	12
	5562 Multiple respiratory virus, nucleic acid detection		•					•				•	
	Specimens: The round contains 3 swab samples. Examinations: Influenza A/B virus NAT, RSV NAT and SARS-CoV-2 NAT	Note: CoV-2	s: Sche assay)	me is r ).	not suit	able fo	r TMA r	nethod	ls (e.g.	Hologic	: Panth	ier SAF	RS-
					_	_	_	_	_	_			
	5669 Mumns virus antibodies	1	2	3	4	5	6	7	8	9	10	11	12
€QA₃	Specimens: 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.	Exam clinica	<b>inatio</b> al inter	<b>1s:</b> Mu pretati	mps vii ion	us IgG a	and IgM	1 antibo	odies a	nd post	t-analy	rtical	
		1	2	2	Α	-	<u> </u>	7	0	0	10	11	17
_		1	2	3	4	5	ь	/	8	9	IU		12
	5675 Norovirus, nucleic acid detection			•			•			•			
	5675 Norovirus, nucleic acid detection			•			•			•			•

	1	2	3	4	5	6	7	8	9	10	11	12
5660 Parvovirus B19, antibodies	3		•			•			•			•
<b>Specimens:</b> 3 liquid human plasma or serum samples, 0.4 mL. Authentic commutable samples: each batch originates from a single human donor.	Examin interpre	<b>ations</b> tation	: Parv	ovirus	lgG, lg	M, IgG	avidity	and po	ost-ana	llytical	clinical	ĘŲĄ
	1	2	3	4	5	6	7	8	9	10	11	12
5560 Puumala virus, antibodies	3*		•			•			•		•	Ę
<b>Specimens:</b> 3 liquid human plasma or serum samples, 0.3 mL. Brief case histories are also provided.	Examin IgG avid Notes: I	ations ity and For clin	: Puur 1 post 1ical Ia	mala v -analy aborat	irus Ig( rtical cl ories a	5, IgM, inical i nd POC	POC te nterpre T sites	ests and etation	d specif	fic anti	bodies,	EŲA
	1	2	3	4	5	6	7	8	9	10	11	12
5673 Respiratory adenovirus, antigen detection	3*		•			•			•			• 3
Specimens: 3 simulated samples, 1 mL	Examina	ations:	Aden	ovirus	Ag							
5000 Determine and adaptation detection	1	2	3	4	5	6	7	8	9	10	11	12
SUSS Rotavirus and adenovirus, antigen detection	*		-		<u> </u>							Ĕ
Specimens: 3 simulated samples, 1 mL	Examin	ations	: Rota	ivirus	and ad	enoviru	us antig	gen det	ection			
FC72 DC views antigon detection	1	2	3	4	5	6	7	8	9	10	11	12
S672 RS Virus, antigen detection	*	•									•	2
Specimens: 3 liquid and/or swab samples. Examinations: RSVAg	Notes: I for IFA o	For clin or NAT	iical la meth	ods, p	ories a lease s	nd POC ee sch	T sites eme 56	. The sa 570 or 5	amples 562.	are no	t suital	ble <u>c</u>
	1	2	3	4	5	6	7	8	9	10	11	12
5667 Rubella virus, antibodies				•			•			•		
<b>Specimens:</b> 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.	<b>Examin</b> analytic	ations al clini	: Rube cal int	ella vir terpre	us IgG tation	and IgI	M antit	odies,	lgG avi	dity an	d post-	· À
	1	2	3	4	5	6	7	8	9	10	11	12
5099 Tick-borne encephalitis virus, antibodies			•			•			•			• Ę
Specimens: 3 liquid human plasma or serum samples, 0.5 mL.	Examin	ations	: TBE	lgG, Ig	M, tot	al antit	odies	and pos	st-anal	ytical c	linical	
donor.	Notes: I	For clin	ical la	borat	ories a	nd POC	T sites					POC
	1	2	2	Л	5	6	7	Q	a	10	11	17
5677 SARS-CoV-2, antibodies		2		•			•			•		
<b>Specimens:</b> 3 liquid human plasma or serum samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.	Examina SARS-C Notes:	ations: oV-2 lg	SARS gA uical la	5-CoV-	2 Ab, S ories a	ARS-C	oV-2 lg	G, SAR	S-CoV-	-2 lgM,		P
	1	2	3	4	5	6	7	8	9	10	11	12
5681 SARS-LOV-2, antigen detection				•			•			•		3
Specimens: 3 simulated samples Examinations: SARS-CoV-2 Ag	Notes: I	For clin	iical la	borat	ories ai	nd POC	T sites					2
	1	2	3	4	5	6	7	8	9	10	11	12
5676 SARS-CoV-2, nucleic acid detection				•			•			•		
Specimens: 3 simulated whole genome cDNA samples Examinations: SARS-CoV-2 NAT	Notes: I (e.g. Ho	ncludi logic P	ng vai anthe	riants. r SAR	Schen S-CoV-	ie is no 2 assav	ot suita y).	ble for	TMA m	nethod	5	POCT

		2	5	4	<b>)</b>	0	/	0	9	10		Т
3 See See See See See See See See See Se	)	•			•			•			•	
Specimens: 3 liquid human plasma or serum samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.	Exami clinica	<b>nation</b> I interp	<b>is:</b> Vari pretatio	cella zo on	ister Igl	G, IgM,	total a	ntibod	lies an	d post-	analyt	i
	1	2	3	4	5	6	7	8	9	10	11	_
5636 Zika virus, antibodies 3					•						•	
<b>Specimens:</b> 3 liquid human plasma or serum samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.	Exami	nation	s: Zika	virus Ig	G, Zika	virus Ig	M, clini	cal inte	erpreta	tion		
2. A selection of the block of the selection of the selection												
QA schemes suitable for direct nucleic acid testin	1 g me	2 2	ds »		tiple	<b>6</b>	7	8	9	10	11	
QA schemes suitable for direct nucleic acid testin 5191 Faecal bacterial pathogens multiplex, nucleic acid detection	1 1		ds » ₃	4 •	tiple ₅	6 •	7	8	9	10	11	
QA schemes suitable for direct nucleic acid testin 5191 Faecal bacterial pathogens multiplex, nucleic acid detection Specimens: 3 samples. Either lyophilized mixtures of bacteria and/or simulated samples, 1 mL. Examinations: Direct nucleic acid detection. Pathogens included are Aeromonas, Campylobacter, E. coli EHEC (stx1/stx2), E. coli EAEC, E. coli EIEC, E. coli EPEC, E. coli ETEC, Plesiomonas, Salmonella, Shigella and Yersinia.	ng me	2 : Durin pathog	g the p	4 • eriod o ill be co	f one conversed.	6 • alenda	7 r year, a	8 a comp	9 orehens	10 •	11 ection	
QA schemes suitable for direct nucleic acid testin 5191 Faecal bacterial pathogens multiplex, nucleic acid detection Specimens: 3 samples. Either lyophilized mixtures of bacteria and/or simulated samples, 1 mL. Examinations: Direct nucleic acid detection. Pathogens included are Aeromonas, Campylobacter, <i>E. coli</i> EHEC (stx1/stx2), <i>E. coli</i> EAEC, <i>E. coli</i> EIEC, <i>E. coli</i> EPEC, <i>E. coli</i> ETEC, Plesiomonas, Salmonella, Shigella and Yersinia.	ng me	2 : Durin pathog	g the p gens w	4 • eriod o ill be cc	f one c. vered.	6 alenda	7 r year, a	8 a comp	9 orehen:	10 • sive sel	11 ection	
QA schemes suitable for direct nucleic acid testin 5191 Faecal bacterial pathogens multiplex, nucleic acid detection Specimens: 3 samples. Either lyophilized mixtures of bacteria and/or simulated samples, 1 mL. Examinations: Direct nucleic acid detection. Pathogens included are Aeromonas, Campylobacter, <i>E. coli</i> EHEC (stx1/stx2), <i>E. coli</i> EAEC, <i>E. coli</i> EIEC, <i>E. coli</i> EPEC, <i>E. coli</i> ETEC, Plesiomonas, Salmonella, Shigella and Yersinia. 5472 Faecal parasites multiplex, nucleic acid detection	1 Notes listed	2 : Durin pathog	g the p gens w	4 eriod o ill be co	f one convered.	6 alenda	7 r year, ; 7	8 a comp	9 prehens	10 • sive sel	11 ection 11 •	
QA schemes suitable for direct nucleic acid testin 5191 Faecal bacterial pathogens multiplex, nucleic acid detection Specimens: 3 samples. Either lyophilized mixtures of bacteria and/or simulated samples, 1 mL. Examinations: Direct nucleic acid detection. Pathogens included are Aeromonas, Campylobacter, <i>E. coli</i> EHEC (stx1/stx2), <i>E. coli</i> EAEC, <i>E. coli</i> EIEC, <i>E. coli</i> EPEC, <i>E. coli</i> ETEC, Plesiomonas, Salmonella, Shigella and Yersinia. 5472 Faecal parasites multiplex, nucleic acid detection Specimens: 3 lyophilized samples	ng me	2 : Durin pathog 2 • nation 5, Ento	g the p gens w 3 3 s: Nuc	4 eriod o ill be co 4 leic aciu	f one covered.	ex 6 alenda 6 tion of	7 r year, a 7 Crypto lamblio	8 a comp 8 esporidi 7.	9 prehens 9 jum, D	10 • sive sel	11 ection 11 • voeba	
QA schemes suitable for direct nucleic acid testin 5191 Faecal bacterial pathogens multiplex, nucleic acid detection Specimens: 3 samples. Either lyophilized mixtures of bacteria and/or simulated samples, 1 mL. Examinations: Direct nucleic acid detection. Pathogens included are Aeromonas, Campylobacter, <i>E. coli</i> EHEC (stx1/stx2), <i>E. coli</i> EAEC, <i>E. coli</i> EIEC, <i>E. coli</i> EPEC, <i>E. coli</i> ETEC, Plesiomonas, Salmonella, Shigella and Versinia. 5472 Faecal parasites multiplex, nucleic acid detection Specimens: 3 lyophilized samples	notes 1 Notes listed 1 Exami fragilis	2 : Durin pathog 2 • nation 5, Ento	g the p gens w 3 3 3 3 3	4 eriod o ill be co 4 leic aciu	f one c. s f one c. vered.	eX 6 alenda 6 tion of <i>G</i>	7 r year, a 7 Crypto lamblio 7	8 a comp 8 • sporidi 7.	9 orehen: 9 ium, D	10 • sive sel 10 ientam	11 ection 11 • oeba	
QA schemes suitable for direct nucleic acid testin 5191 Faecal bacterial pathogens multiplex, nucleic acid detection Specimens: 3 samples. Either lyophilized mixtures of bacteria and/or simulated samples, 1 mL. Examinations: Direct nucleic acid detection. Pathogens included are Aeromonas, Campylobacter, <i>E. coli</i> EHEC (stx1/stx2), <i>E. coli</i> EAEC, <i>E. coli</i> EIEC, <i>E. coli</i> EPEC, <i>E. coli</i> ETEC, Plesiomonas, Salmonella, Shigella and Versinia. 5472 Faecal parasites multiplex, nucleic acid detection Specimens: 3 lyophilized samples	ng me	2 2 anation 2 2 2	3 g the p gens w 3 is: Nucc is: Nucc armoebu	4 eriod o ill be co	f one c. vered.	ex 6 • alenda 6 tion of <i>G</i>	7 r year, a 7 Crypto Iamblio 7	8 a comp 8 esporidi 7. 8	9 rrehen: 9 ium, D	10 • sive sel 10 ientam	11 ection 11 • oeba	
QA schemes suitable for direct nucleic acid testin 5191 Faecal bacterial pathogens multiplex, nucleic acid detection Specimens: 3 samples. Either lyophilized mixtures of bacteria and/or simulated samples, 1 mL. Examinations: Direct nucleic acid detection. Pathogens included are Aeromonas, Campylobacter, <i>E. coli</i> EHEC (stx1/stx2), <i>E. coli</i> EAEC, <i>E. coli</i> EIEC, <i>E. coli</i> EPEC, <i>E. coli</i> ETEC, Plesiomonas, Salmonella, Shigella and Versinia. 5472 Faecal parasites multiplex, nucleic acid detection Specimens: 3 lyophilized samples 5304 Gastrointestinal viral multiplex, nucleic acid detection Specimens: 2 simulated camples 1 ml	1 Notes listed	2 c Durin pathog 2 • nation 5, Enter 2	3 g the p g th	4 eriod o ill be co	f one covered.	ex 6 alenda 6 tion of <i>iardia</i> 6	7 r year, a 7 Crypto lambliu 7	8 a comp sporidi a. 8 a	9 rehen: 9 	10 • sive sel 10 ientam	11 ection 11 • oeba 11	

5303 Meningitis-encephalitis multiplex, nucleic acid detection (1

Specimens: 3 simulated samples, 1 mL.

Examinations: Direct multiplex nucleic acid detection. Pathogens included are: Escherichia coli K1, Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitidis, Streptococcus agalactiae, Streptococcus pneumoniae, Cytomegalovirus (CMV), Enterovirus, Epstein-Barr virus (EBV), Herpes

9

•

10

11

•

12

simplex virus 1 (HSV1), Herpes simplex virus 2 (HSV2), Human herpesvirus 6 (HHV6), Human parechovirus (HPeV), Varizella zoster virus (VZV) and Cryptococcus neoformans/gattii.

•

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

5300 Respiratory infections multiplex, nucleic acid detection 🦯		•	3	4	•	6	7	8	•	10	11	12
Specimens: 4 simulated samples, 1 mL Examinations: Direct multiplex nucleic acid detection. Pathogens included are adenovirus, <i>B. parapertussis, B. pertussis, C. pneumoniae,</i> coronavirus (OC43, 229E, NL63, HKU1), enterovirus, influenzavirus A/B, <i>L. pneumophila,</i> metapneumovirus, <i>M. pneumoniae,</i> parainfluenzavirus 1-4, rhinovirus, RSV A/B, SARS-CoV-2 and <i>S. pneumoniae.</i>	Note: listed	: Durin pathos្	g the p gens wi	eriod o ill be co	f one c vered.	alenda	r year, a	a comp	rehens	sive sel	ection	of
	1	2	3	4	5	6	7	8	9	10	11	1.
5302 Sexually transmitted diseases multiplex,			•		•			•			•	

(1

•

Specimens: 4 simulated swab/urine samples, 2 mL

Examinations: Direct multiplex nucleic acid detection. Pathogens included are C. trachomatis, M. genitalium, M. hominis, N. gonorrhoeae, T. vaginalis, U. parvum and U. urealyticum.

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

### EQA schemes for microbiology POCT

#### Microbiology

- 5640 EBV mononucleosis, POCT
- 5635 Dengue virus, antibodies and antigen detection
- 5860 *Helicobacter pylori*, antibodies 5596 *Helicobacter pylori*, antigen detection in faeces
- 5090 HIV, antibodies and antigen detection, POCT
- 5671 Influenza virus A+B, antigen detection
- 5597 Legionella, antigen detection in urine
- 5430 Malaria, antigen and nucleic acid detection
- 5980 Mycoplasma pneumoniae, antibodies
- 5560 Puumala virus, antibodies
- 5673 Respiratory adenovirus, antigen detection
- 5098 Rotavirus and adenovirus, antigen detection
- 5672 RS virus, antigen detection
- 5677 SARS CoV-2, antibodies
- 5681 SARS-CoV-2 antigen detection
- 5676 SARS-CoV-2 nucleic acid detection
- 5595 Streptococcus pyogenes, group A, antigen detection in pharyngeal sample
- 5599 Streptococcus agalactiae (GBS), nucleic acid detection
- 5598 Streptococcus pneumoniae, antigen detection in urine
- 5099 Tick-borne encephalitis virus, antibodies
- 5473 Trichomonas vaginalis, detection

## LABQUALITY

## Sales and customer service

Tel. +358 9 8566 8200 | Fax +358 9 8566 8280 info@labquality.fi | www.labquality.com Kumpulantie 15, FI-00520 Helsinki, Finland VAT FI01100791